Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UVA critical wavelength method inadequate to predict potential UVA absorption -- L'Oreal.

This article was originally published in The Tan Sheet

Executive Summary

CRITICAL WAVELENGTH TEST INADEQUATE TO DETERMINE UVA EFFICACY, L'OREAL maintains in May 15 comments to FDA on the OTC sunscreen tentative final monograph. Following a study evaluation of the proposed in vitro critical wavelength testing method, L'Oreal says it found the test "does not provide a quantitative measure of the UVA protection afforded" by an OTC sunscreen. "Since this method does not account for any biological response, it cannot adequately predict a product's protection against UVA effects on the skin," the company asserts. L'Oreal is working on an alternative testing method to measure UVA protection in sunscreens.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel